Erythrocyte magnesium concentrations and NIPA1/NIPA2 gene expression in children with autism spectrum disorder

Erythrocyte magnesium concentrations and NIPA1/NIPA2 gene expression in children with autism spectrum disorder. Download PDF Abstract While genetic and environmental factors are involved in Autism Spectrum Disorder (ASD), the role of magnesium (Mg 2+) homeostasis remains a burgeoning field of interest. This cross-sectional study analyzed the association between erythrocyte Mg 2+ concentrations, clinical characteristics, and the expression of Mg 2+ transporter genes ( NIPA1 and NIPA2) in children with and without ASD.

Intracellular Mg 2+ levels were determined, and relative gene expression was evaluated to detect molecular trends. The unadjusted analyses initially demonstrated lower erythrocyte Mg 2+ concentrations in children with ASD. This statistical association was completely attenuated after adjusting for clinical confounding variables, such as selective eating habits and pharmacotherapy.

This indicates that the observed variations in Mg 2+ levels are influenced by these clinical covariates rather than constituting an intrinsic biological biomarker of autism. Concurrently, multivariable analysis adjusted associations with ASD status regarding NIPA1 and NIPA2 gene expression, highlighting complex metabolic and genetic trends that require cautious interpretation due to reference gene instability. In conclusion, these findings suggest that behavioral and pharmacological factors significantly alter traditional metabolic markers, emphasizing the need for multi-reference gene panels in future prospective neurodevelopmental research to ensure solid biological validation.

A major analysis suggests Phelan-McDermid syndrome, a genetic disorder closely linked to autism, may affect about 1 in 7,300 people and more than 45,000 Americans. Researchers warn that thousands of cases may remain hidden because genetic testing is often not performed, even as targeted treatments move into clinical trials.

This “rare” autism-linked genetic disorder may be far more common than scientists thought. Com New research led by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai suggests that Phelan-McDermid syndrome (PMS) may be much more common than earlier estimates indicated.

The findings, published in Autism Research, estimate that the condition affects roughly 1 in 7,300 people. Phelan-McDermid syndrome is a rare genetic disorder caused by a deletion or mutation involving the SHANK3 gene on chromosome 22.

It can lead to a broad range of medical, intellectual, and behavioral challenges. Most people with the syndrome also meet the criteria for autism spectrum disorder, and changes affecting SHANK3 are believed to account for as many as one percent of autism spectrum disorder cases.

Genetic Data Reveal a Much Larger Population To estimate how common the condition may be, Mount Sinai researchers worked with genetic testing laboratories, academic medical centers, and autism research programs.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.